🇪🇺 ACT-132577 in European Union

EMA authorised ACT-132577 on 29 January 2026

Marketing authorisation

EMA — authorised 29 January 2026

  • Application: EMEA/H/C/006080
  • Marketing authorisation holder: Idorsia Pharmaceuticals Deutschland GmbH
  • Local brand name: Jeraygo
  • Indication: Treatment of resistant hypertension
  • Status: approved

The European Medicines Agency (EMA) has approved Jeraygo (ACT-132577) for the treatment of resistant hypertension. This approval was granted on 29 January 2026, following a standard marketing authorisation application. Jeraygo is manufactured by Idorsia Pharmaceuticals Deutschland GmbH.

Read official source →

Frequently asked questions

Is ACT-132577 approved in European Union?

Yes. EMA authorised it on 29 January 2026.

Who is the marketing authorisation holder for ACT-132577 in European Union?

Idorsia Pharmaceuticals Deutschland GmbH holds the EU marketing authorisation.